How much funding has HI-Bio raised?

HI-Bio has raised $215.0M in total funding, most recently a Series B round.

Where is HI-Bio headquartered?

HI-Bio is headquartered in South San Francisco, California, United States.

What industry is HI-Bio in?

HI-Bio operates in Biotech, Healthcare.

HI-Bio

Closed

Precision therapies for immune-mediated disease.

South San Francisco, United States · Founded 2020 · $215.0M raised

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 11–50
Founded: 2020
Business Model: B2B

Website: hi-bio.com
Total Funding: $215.0M
Last Round: $95.0M Series BJan 2024
Rounds: 2

About

HI-Bio is a clinical-stage biotechnology company developing precision therapies for severe immune-mediated diseases. The company's pipeline targets conditions with high unmet need including IgA nephropathy, atopic dermatitis, and alopecia areata, using a mechanism-based approach to selectively disrupt disease-driving immune pathways. Founded in 2020 and headquartered in South San Francisco, HI-Bio raised $70M in Series B financing in October 2023 before being acquired by Gilead Sciences in 2024 for approximately $1.15 billion.

Summary

HI-Bio is a Biotech company based in South San Francisco, United States, founded in 2020. It has raised $215.0M in total across 2 rounds, most recently a $95.0M Series B round in Jan 2024.

LinkedIn X (Twitter)GitHub